GKB OPHTHALMICS LTD.

GKB Ophthalmics Ltd has announced that its Board of Directors will convene on November 12, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company has also informed that the trading window for designated persons will reopen 48 hours after the submission of these financial results to the stock exchange. The notice is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GKB Ophthalmics Ltd has announced the closure of its trading window for dealing in the company's shares. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from October 01, 2026, until 48 hours after the declaration of the financial results for the quarter ended September 30, 2026. All directors, designated persons, and their immediate relatives are prohibited from trading in the company's shares during this period. The date of the board meeting to consider these financial results will be communicated separately.

GKB Ophthalmics Ltd held its 44th Annual General Meeting on August 25, 2026. The meeting, held at the company's registered office in Goa, was attended by directors, auditors, and key management personnel. The Chairman provided an overview of the company's performance for the financial year 2025-26, noting significant global economic uncertainty. Due to operating losses, no dividend was declared for the financial year 2025-26. The company facilitated e-voting for resolutions, with options for poll voting at the meeting for members who had not voted remotely. The adoption of standalone financial statements was among the ordinary business items.

GKB Ophthalmics Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company submitted these results along with the Limited Review Reports as required by SEBI regulations. The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and reviewed by the statutory auditors. The results cover both standalone performance and consolidated group performance, including subsidiaries and associates.

GKB Ophthalmics Ltd. announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors took on record these results during a meeting held on August 12, 2026. The company is challenging a recovery proceeding of ₹8,82,00,856/- by filing a writ petition. Additionally, its wholly-owned subsidiary, GKB Ophthalmics Products FZE, completed the closure of its step-down subsidiary, Prime Ophthalmics Products PTY Limited, due to revenue challenges, resulting in a write-off of AED 1,69,325.58. The legal structure of another subsidiary, Prescription Optical Products LLC, was updated to a Single Owner LLC.

GKB Ophthalmics Ltd has dispatched a letter to shareholders whose email addresses are not registered, providing a web link to access the Annual Report for FY 2025-26. This action is in compliance with Regulation 36(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The company also announced its 44th Annual General Meeting (AGM) scheduled for August 21, 2026, at its registered office in Mapusa, Goa. The communication serves as a reminder for shareholders to update their KYC details, including PAN, address, bank account, and nomination, as mandated by SEBI, to ensure continued receipt of payments like dividends and to facilitate electronic transactions.

GKB Ophthalmics Ltd announced that its Register of Members and Share Transfer Books will be closed from August 19, 2026, to August 25, 2026, inclusive. This closure is for the purpose of the company's 44th Annual General Meeting (AGM), scheduled for August 25, 2026. The company also stated that no dividend is proposed for the financial year 2025-26. This notice is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013.

GKB Ophthalmics Ltd. has filed its Annual Report for the financial year 2025-26, along with the Notice of the Annual General Meeting (AGM). The report details the company's performance and includes financial statements, directors' reports, and corporate governance information. The AGM is scheduled for August 25, 2026, at the company's registered office in Mapusa, Goa. Key agenda items include the adoption of standalone and consolidated financial statements for FY 2025-26, and the re-appointment of Mr. Vikram Gupta and Mr. Cedric Lobo to the board.

GKB Ophthalmics Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has also informed that the trading window for designated persons, which was closed from July 01, 2026, will reopen 48 hours after the submission of these financial results to the stock exchange. This notice adheres to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GKB Ophthalmics Ltd has received a 'Notice of Demand' from the Mamlatdar of Bardez Taluka, Goa, for the recovery of ₹8,82,00,856/-. This demand is in relation to an order passed by the Labour Commissioner on September 04, 2025, for the execution of an award dated May 25, 2021, by the Industrial Tribunal. The company is challenging the award via a writ petition before the High Court of Bombay at Goa. GKB Ophthalmics plans to challenge the latest recovery order by filing another writ petition. The notice requires payment within 10 days of service, which was July 13, 2026.